Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295,919 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN. Weber JS, et al. Among authors: wang y, wang t. Cancer Immunol Immunother. 2023 Apr;72(4):945-954. doi: 10.1007/s00262-022-03302-5. Epub 2022 Oct 5. Cancer Immunol Immunother. 2023. PMID: 36197494 Free PMC article. Clinical Trial.
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, Puig L. Armstrong AW, et al. Among authors: wang y. Dermatol Ther (Heidelb). 2022 Dec;12(12):2867-2870. doi: 10.1007/s13555-022-00812-z. Epub 2022 Oct 21. Dermatol Ther (Heidelb). 2022. PMID: 36271222 Free PMC article. No abstract available.
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS, Poretta T, Stwalley BD, Sakkal LA, Du EX, Wang T, Chen Y, Wang Y, Betts KA, Shoushtari AN. Weber JS, et al. Among authors: wang y, wang t. Cancer Immunol Immunother. 2023 Apr;72(4):955. doi: 10.1007/s00262-022-03351-w. Cancer Immunol Immunother. 2023. PMID: 36538061 Free PMC article. No abstract available.
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
Mysler E, Burmester GR, Saffore CD, Liu J, Wegrzyn L, Yang C, Betts KA, Wang Y, Irvine AD, Panaccione R. Mysler E, et al. Among authors: wang y. Adv Ther. 2024 Feb;41(2):567-597. doi: 10.1007/s12325-023-02732-6. Epub 2024 Jan 2. Adv Ther. 2024. PMID: 38169057 Free PMC article. Review.
295,919 results
You have reached the last available page of results. Please see the User Guide for more information.